Breaks Categories: News

MondayJan 23, 2023 1:08 pm

BioMedNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Redeemable Digital Coupons Now Available for Shareholders of Record

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced availability of its redeemable digital coupons for shareholders of record to claim on Upstream’s trading app. Upon successful claim, shareholders may redeem the digital coupon for a gift package of company products valued at over $179 or trade with others globally on Upstream to bring new potential customers into the community. The announcement reads, “By incorporating Upstream’s Web3 digital coupons into our strategy, we aim to provide our shareholders with first-hand experience of our products and bring new potential customers into our community to drive…

Continue Reading

MondayJan 23, 2023 12:59 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference

QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at the Emerging Growth Conference at 10:15 a.m. ET on Wednesday, Jan. 25, 2023. Leading QSAM’s presentation will be the company’s CEO Douglas Baum and other executive officers, who may subsequently open the floor for questions. Interested parties should visit https://ibn.fm/P2xIR to register to attend the conference and receive any updates. An archived webcast will be made available on EmergingGrowth.com and on the Emerging Growth YouTube…

Continue Reading

MondayJan 23, 2023 10:58 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. According to the update, the study used an industry-standard animal model to compare weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours prior to infection experienced no significant weight loss over the six-day trial, whereas the untreated control group’s weight declined 12% on average, a highly statistically significant difference (p<0.0005). “We…

Continue Reading

FridayJan 20, 2023 11:05 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Correction Regarding $4.1M Registered Direct and Private Placement

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, on Thursday announced its entry into a definitive agreement with investors in a registered direct offering, as well as details surrounding a concurrent private placement. The company issued an update to the initial release to correct the final share count and closing date. The registered direct offering is for the purchase and sale of 4,315,787 shares. In a concurrent private placement, Jupiter Wellness also agreed to issue to the same investors a total of 8,631,574 warrants to purchase up to one share of common stock, each at…

Continue Reading

ThursdayJan 19, 2023 11:46 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces $4.1M Registered Direct and Private Placement

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced its entry into a definitive agreement with investors for the purchase and sale of 4,315,786 shares in a registered direct offering. In a concurrent private placement, Jupiter Wellness also agreed to issue to the same investors a total of 8,631,572 warrants to purchase up to one share of common stock, each at an exercise price of $1.00. The private placement warrants will be exercisable beginning six months after issuance, with 4,315,786 having a 3-year term and 4,315,786 having a 5-year term from the initial exercise…

Continue Reading

ThursdayJan 19, 2023 11:23 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pharma’s recent submission of its clinical trial application for an upcoming phase a trial evaluating Lucid-MS. A candidate for treatment of multiple sclerosis (“MS”), Lucid-MS is a first-in-class neuroprotective compound featuring a novel mechanism action that has been shown to prevent myelin degradation, or demyelination, a significant cause of MS and other neurodegenerative diseases. According to the announcement, Lucid-MS…

Continue Reading

WednesdayJan 18, 2023 1:36 pm

BioMedNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Makes News in Finding Missing Woman

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, last week announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec, a location-awareness technology company. Expected to close on or before March 17, 2023, the acquisition will include TrakTec’s active paying subscriber base, police department contracts, commercial ready tracking products, and backend platform and mobile app. TrakTec offers affordable, scalable location-awareness technology solutions and operates iGPS Watches and SafetyNet(R) Tracking Systems that provide a range of enhanced monitoring services. These important services were demonstrated recently, as TrakTec’s SafetyNet system made…

Continue Reading

WednesdayJan 18, 2023 10:36 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from the feasibility study are very promising and provide further insights into the potential of this cutting-edge wearable technology to quantify neural activity and changes in brain biomarkers during the administration of psychedelics. The possibility of using this technology to develop a predictive tool to aid…

Continue Reading

TuesdayJan 17, 2023 12:04 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits Phase-1 Clinical Trial Application for Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced its submission of a Clinical Trial Application (“CTA”) for a planned phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclerosis (“MS”). “This is an exciting time for our company, shareholders and, most importantly, for the MS community,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma. “Multiple sclerosis is a debilitating disease without any cure, relegating patients and caregivers to…

Continue Reading

TuesdayJan 17, 2023 11:49 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Among First of Nasdaq Companies to Dual List on Upstream

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, last week became the second NASDAQ company to dual list on Upstream under the ticker symbol JUPW. Jupiter Wellness released a digital collectible NFT to commemorate the dual listing, which is available for all Upstream participants to claim with the code “JUPW.” “We are thrilled to be among the first companies to dual list on Upstream’s next generation marketplace,” said Jupiter Wellness CEO Brian John. “We are adding new value to our shareholders while expanding our company and mission to a modern, global investor-base.” To view the…

Continue Reading